Navigation Links
Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/12/2009

ber 2008 Transcept submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Intermezzo® as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009 Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products, L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States. For further information, please visit the company's website at: www.transcept.com.

The United States Patent and Trademark Office granted a Notice of Allowance for claims that cover Intermezzo® under U.S. patent application no. 11/833,323. If issued, this patent will expire in 2025. Transcept is actively pursuing additional patents to protect Intermezzo® in the United States and key non-U.S. markets, and, as part of the NDA submission, has requested that the FDA grant three years of Hatch-Waxman marketing exclusivity to Intermezzo®.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. For further information, please visit the company's website at: www.transcept.com.

Forward Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenues, projected expenses, prospects, plans and objectives of man
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
2. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
3. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
4. Transcept Pharmaceuticals to Report First Quarter 2009 Results
5. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
6. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
7. Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results
8. Onyx Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
9. Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA
10. Endo Pharmaceuticals and LecTec Settle Patent Dispute
11. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, 2014 ... ;  Sorrento), an oncology company developing new treatments ... a privately-held immuno-oncology company developing proprietary Neukoplast ® ... therapy, announced today that the companies have entered ... generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for the ...
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ... of the "Micro Market Monitor: North American ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... progressing steadily, which has resulted in fueling the ... The main purpose of these dermatology devices is ...
(Date:12/19/2014)... Capnia, Inc. (NASDAQ: CAPN ... based on its proprietary Sensalyze™ Technology Platform for ... results for the third quarter and nine months ... completion of our initial public offering (IPO), we ... initiated CoSense® commercial launch," said Anish Bhatnagar, M.D., ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8
... 2011 Cumberland Pharmaceuticals Inc. (Nasdaq: ... care and gastroenterology markets, today announced fourth quarter and full ... For the three months ended December 31, 2010, net revenue ... corresponding period in 2009. This quarterly revenue growth was largely ...
... Hill-Rom Holdings, Inc. (NYSE: HRC ) today ... immediately. "I am pleased to have someone of ... Mark Guinan, Senior Vice President and Chief Financial Officer of ... will contribute to the solid financial leadership of our company ...
Cached Medicine Technology:Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 2Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 3Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 4Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 5Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 6Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 7Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 8Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 9Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 10Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 11Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 12Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 13
(Date:12/19/2014)... (PRWEB) December 19, 2014 Diet Doc ... date, current approach to weight loss by ... understanding. The professionals at the company understand that remaining ... side effects of eliminating carbohydrates and sugars from the ... tempted to abandon their weight loss goals. , ...
(Date:12/19/2014)... The global magnetic resonance imaging (MRI) ... is saturated with numerous players developing innovative technologies. ... as non-invasive nature, MRI systems have seen continued ... healthcare market. Rapid advances in the field imaging ... have greatly expanded the potential of therapeutic applications. ...
(Date:12/19/2014)... 19, 2014 If you have ever ... breathing, you probably wished you had an arsenal of ... cystic fibrosis, and other breathing disorders. Currently, the only ... avoiding triggers, but other common treatments do exist. ... in San Antonio, TX, 34 asthma educators responded to ...
(Date:12/19/2014)... 19, 2014 This is a professional ... global Gliquidone industry with a focus on the Chinese ... status of the Gliquidone manufacturers and is a valuable ... interested in the industry. , Firstly, the report provides ... applications and manufacturing technology. Then, the report explores the ...
(Date:12/19/2014)... 2014 (HealthDay News) -- A new study suggests a ... severe hot flashes and night sweats -- and higher ... flashes are common during menopause, affecting about 60 percent ... women after menopause, since they then face a higher ... suggest women who exhibit moderate or severe menopausal symptoms ...
Breaking Medicine News(10 mins):Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 3Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 4Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 2Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 4Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 2Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2
... new study has shown that vision correction patients will ... Lasek surgery. Both types of surgeries are equally safe ... cut flaps in the cornea and rectify the shape. ... surface of the cornea. This helps in doing away ...
... report has suggested that Thursday may not be a good day ... might end up waiting longer in the hospital.// ,The ... the trend for five years have blamed the procedures in the ... requirements, as it is thought to be. ,It was ...
... have been warned about a potential hepatitis risk for those ... ,Authorities suspect that those who consumed food from McDonald's ... of contracting Hepatitis A. The medical officer confirmed that a ... was suffering the highly infectious stage of the virus. It ...
... million U.S. dollars to take the anti-bird flu initiative forward, in ... for 2007 as// compared to the spending allocated in 2006. ... bird flu control, Bayu Krishnamurthi, the added spending on bird flu ... drive. So far there have been 74 human cases of bird ...
... by scientists, promises protection against all strains of flu virus. It ... influenza A virus, that is the cause of outbreaks of both ... vaccine is expected to bestow life long immunity. The only other ... every year. ,The injection is yet to be ...
... Highly developed nations like the U.S, with a fast paced lifestyle ... of saturated fat which can cause an// avalanche of diseases. ... eat more and put on more weight, proves a recent ... adults who live with children that those who live without children ...
Cached Medicine News:
... OPTIMA is a fully automated microplate ... different measurement principles:, , Fluorescence Polarization ... Fluorescence , High-Performance Luminescence (flash ... ,It is designed for the ...
... cell based assays, in 6 to 1536 ... detection, Fusion is the instrument that can ... to use the AlphaScreen assay platform. ... system: Reads AlphaScreen (Amplified Luminescent Proximity ...
VICTOR2 V measures prompt fluorescence, fluorescence polarization, luminescence, time-resolved fluorescence and absorbance. This model includes high density TRF (for 1536-well plates), temperature ...
... is the modular VICTOR2 ... high density TR-fluorometry, stacker ... The extra high density ... excitation beam for TRF ...
Medicine Products: